ACCURATE

Detection rate of > 99% for Trisomies 21, 18 und 13

LOW-PRICED

PreviaTest – the NIPT at a fair and affordable price

COMPREHENSIV

Screens for more than 80 Microdeletion or  Microduplikation syndromes

Non-Invasive Prenatal Test: From gestational week 11 onwards (10 weeks + 0 days)

Congratulations on your pregnancy!

Over 3.5 million women worldwide have already trusted our PreviaTest and its underlying technology. Together with one of the world’s largest providers of genetic testing, we would like to assist you during your pregnancy. Now we are pleased to also offer you a comprehensive screening at a reasonable price.  

The non-invasive PreviaTest

PreviaTest screens for the three most common trisomy conditions present at birth, Down Syndrome, Edwards Syndrome and Patau Syndrome. Independent validation studies, including the world’s largest study on the use of NIPT in clinical practice in nearly 147,000 women, have shown an accuracy rate of over 99% for detection of these conditions and a very low false-positive rate of 0.05%*. This means that fewer women will undergo invasive diagnostic procedures such as amniocentesis or chorionic villus sampling, which carry a 1-2% risk of miscarriage. PreviaTest is non-invasive and therefore poses no risk to the mother or baby.

Determining the gender of your baby is an option you can request at no extra charge.

The high accuracy of PreviaTest

Validation studies show a detection rate of 99.5% for Trisomies 21, 18 and 13. The underlying technology of PreviaTest has been validated with the world’s largest study of the clinical performance of NIPT with data calculated from the outcomes of over 146,000 pregnancies**.

Trisomy Sensitivity Specificity PPV NPV
T21
99.17 %
99.95 %
97.58 %
99.99 %
T18
98.24 %
99.95 %
97.67 %
100.00 %
T13
100.00 %
99.96 %
83.33 %
100.00 %

Learn more by using PreviaTest

The PreviaTest additionally screens for:

  • Sex Chromosomal Abnormalities (SCAs)
  • Aberrations of other chromosomes
  • Microdeletion/Microduplications Syndromes

Additionally, incidental findings will be reported. In microdeletions / microduplications small pieces of a chromosome are missing or the same piece is found twice. Most microdeletions are very rare and the carriers of such microdeletions can have heterogenous phenotypes, depending on many factors. The most common microdeletion affects chromosome 22, the reason why it is called 22q11.2 Microdeletion Syndrome.  The incidence rate is around 1 in 4,000 births.

With PreviaTest you can screen for most deletions and microdeletions as well as duplications and microduplications (currently over 80). It is estimated that deletions, microdeletions, duplications and microduplications occur in about 1 in every 1,000 newborns and that the incidence rate does not depend on the mother’s age. Frequent microdeletion syndromes include:

Region Relevant Syndromes Prevalence
22q11.21
DiGeorge Syndrome
1/4,000
1p36
Chromosome 1p36 deletion Syndrome
1/5,000
7q11.23
Williams-Beuren Syndrome
1/7,500
15q11.2
Prader-Willi/Angelman Syndrome
1/10,000
17p11.2
Smith-Magenis Syndrome
1/15,000
5p
Cri du chat Syndrome
1/20,000
4p16.3
Wolf-Hirschhorn Syndrome
1/50,000
17p13.3
Miller-Dieker Syndrome
1/100,000

PreviaTest – From gestational week 11 onwards

PreviaTest is available for all pregnant women from gestational week 11 onwards (10 weeks + 0 days).PreviaTest Nifty Test NIPT ivf microduplications microdeletions egg-donor

Under specific conditions applicable to the following:

  • Vanishing twin
  • Stem-cell or immune therapy
  • Organ transplant

PreviaTest Report

You will usually get your PreviaTest report in 7-10 calendars days after the blood draw. The report can tell you if the there is a high or low risk that your baby is affected by a genetic syndrome. If the report shows a high risk, then invasive diagnostic testing is recommended.

Scientific studies

PreviaTest corresponds to BGI’s NIFTY and NIFTYPro Test. There are more than 40 scientific publications on the test and the technology. Find out more information on the studies here.

Comprehensive Testing – favorable prices

Syndromes PreviaTest screens for Option 1 Option 2 Option 3
Trisomy 21
Trisomy 18
Trisomy 13
Gender(optional)
Monosomy X (Turner Syndrome)
XXY (Klinefelter Syndrome)
XXX (Triple-X Syndrome)
XYY (Jacobs Syndrome)
Trisomy 9
Trisomy 16
Trisomy 22
22q11.2 Microdeletion Syndrome
More than 80 additional Microdeletion/ Microduplication Syndromes
Report of Incidental Findings

Option 1 is available for twin pregnancies.

We express our recommendation of Ultrasound as an important part of prenatal care.

PreviaTest screens for fetal chromosomal aberrations. It complements the ultrasound of your physician and does not replace the ultrasound in any case.

Remember, it is always important to consult a qualified healthcare professional before taking any genetic test to make sure you fully understand the conditions being tested for. PreviaTest is a screening test: If the test result shows a high risk for a screened condition, it is recommended to have a diagnostic test for confirmation.

Please consider that non-invasive prenatal testing can be appropriate for you but at the same time unsuitable. Before having non-invasive prenatal testing, you should consult a qualified healthcare professional to make sure you fully understand all the relevant risks, diagnoses, therapy options and possible consequences and medical concerns.

Established Quality

PreviaTest corresponds to BGI’s NIFTY and NIFTYPro Test. Therefore, PreviaTest is certified by the following organisations:

PreviaTest Zertifikate Certificates

Where can I get PreviaTest?​

Ask your gynecologist about PreviaTest. Show PreviaTest to your doctor using this info material.

Would you like us to talk to your doctor? Please fill out the following form:

I agree that the information/data I provide will be transmit and processed. Additional information concerning the data processing are available under our terms of use.

[*] Wei Wang et al.(2015), Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146 958 pregnancies, Journal of Ultrasound in Obstetrics and Gynecology.

[**] Samples were collected between Jan 2011 and Aug 2013. The study was published in the Journal of Ultrasound in Obstetrics and Gynecology. Data above are the combination of clinical study and laboratory calculation.

PreviaTest is offered by our partner laboratory BGI Health and is processed at by BGI in Hong Kong.

PreviaTest corresponds to the NIFTY Test technology. NIFTY is a registered trademark of BGI Health.

BGI is registered office is at: Co., Ltd. 16 Dai Fu Street, Tai Po, Hong Kong.

PreviaTest is a registerd trademark of Eluthia GmbH: Im Bosseldorn 30, 69126 Heidelberg, Germany.

Close Menu